(Q44104839)

29 November 2017

title

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England (English)

1 reference

29 November 2017

3

1 reference

29 November 2017

5

Mark Jit

1 reference

29 November 2017

4

Elizabeth Miller

1 reference

29 November 2017

Albert Jan van Hoek

1

1 reference

29 November 2017

Yoon Hong Choi

series ordinal

2

1 reference

29 November 2017

language of work or name

English

0 references

publication date

23 October 2012

1 reference

29 November 2017

1 reference

29 November 2017

volume

30

1 reference

29 November 2017

issue

50

1 reference

29 November 2017

page(s)

7205-7213

1 reference

The current burden of pneumococcal disease in England and Wales

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Use of pneumococcal polysaccharide vaccine in children: what is the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Evolving microbiology of complicated acute otitis media before and after introduction of the pneumococcal conjugate vaccine in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

The potential cost-effectiveness of infant pneumococcal vaccines in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.017

10.1016/J.VACCINE.2012.10.017

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference